TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: electroencephalographic power during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Self Management Skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood biochemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of anti-velmanase alfa-IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enrollment success
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Antibiotics consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual Analog Score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WOMAC function change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Procedural, Serious, and Device-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Young-Mania Rating Scale (Y-MRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change from baseline of total headache score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline of total duration of migraine attack (hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline of migraine frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cancer Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who smoke cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants involved in harmful alcohol drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of zirconia RBFDPs
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Survey of Well-being of Young Children (SWYC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Pediatric Symptom Checklist-17 (PSC-17)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change in mean pulmonary artery pressure (mPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Retinal blood flow (RBF) with oxygen inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants With a Risk of Hospitalization Due to Any Diagnosis Within 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of Death Due to Any Cause During 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Reporting of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximum vessel wall volume of the carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Concentration (Cmax) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve(0-τ) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-20 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: determination of limb volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: determination of shoulder and upper extremity functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assesment of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity, specificity and accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary AKI biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in fractional uric acid excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biologically Verified Cigarette Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay (LOS) at the emergency room
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Serum concentration over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical parameters (heart rate, blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychomotor tests (such continuous attention)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST2.0)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to Refills and Medications Scale (ARMS)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: retinal microvascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Accidental removal
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with metastatic relapse
Endpoint domain: Mortality/survival
Primary endpoint: Expression of CD40L and cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of LVEF(%) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of preoperative intravitreal ranibizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Increased Immune Cell Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac troponin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Use of Movement Integration Strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Cancer Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Lung Cancer Death Rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in Central Line Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Central Line Related Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Closure rate of Macular hole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline patient report of physician performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of internet-based protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Identification of alleles for lung cancer predisposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved vocational outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Correlation between NIRS saturation and oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between NIRS saturation and lactate data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial fibrillation-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Birth defects
Endpoint domain: Mortality/survival
Primary endpoint: Changing volume of benign thyroid nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changing greatest dimension of benign thyroid nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovarian Cancer Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Ovarian Cancer Death Rates
Endpoint domain: Mortality/survival
Primary endpoint: Molecular defect identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Estrogen Receptor (ER) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shared Decision Making Assessment Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Adjustment Scale for Individuals with Ostomy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects with a viable abdominal wall transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Participants Free of Any Protocol-defined Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Ocular and Systemic (Non-Ocular) Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence, Severity, and Duration of Adverse Event of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Nonalcoholic Steatohepatitis (NASH) with no Worsening of Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Grade 3+ Adverse Events Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Nonrelapse mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of laboratory confirmed or serologically symptomatic infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: whole body and lesional 124I uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of SARS-nCoV-2 in the Tear Film
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of lesions correctly evaluated as at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquired Capability for Suicide Scale - Fearlessness About Death (ACSS-FAD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Suicide Scale (BSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of the First Event of the Composite Events
Endpoint domain: Mortality/survival
Primary endpoint: False negative biopsies
Endpoint domain: Adverse events/effects
Primary endpoint: Natural history of sexual and reproductive health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Discontinuation of medication
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mass density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Areal Bone Mineral Density at Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Areal Bone Mineral Density at Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Who Scheduled or Completed Cervical Cancer Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Responders for Baricitinib at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Cancer Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Prostate Cancer Death Rates
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Treatment Regimen Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post infusion recovery of the Test platelets compared to fresh platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post infusion lifespan of Test platelets compared to fresh platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Harm Behavior Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes Beck Scale for Suicidal Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Interpersonal Needs Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of participants with local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: abuse liability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriatic arthritis disease activity score (PASDAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Endoscopic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA50 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: concentration of Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentration of Creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of Myoglobine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of Lactate dehydrogenase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentration of Alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lund-Mackay sinus computed tomography (LMK-CT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombospondin-1 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in injury recidivism
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in alcohol problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of individuals who serorevert
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Food Allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactive Airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative infant exposure to breast milk micro-transcriptome components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in daily number of cigarettes smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with unplanned hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of participants with planned hospital admissions that are found to be necessary
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of emergency department revisits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall response rate (complete + partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with severe BPD or dead
Endpoint domain: Mortality/survival
Primary endpoint: Relapses Post Partum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of cardiac specific enzyme Troponin (cTnl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in behavioral assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRI morphological criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cerebral perfusion by SPECT / PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of upper extremity skills assessment (QUEST)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501A
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) assessed per Independent Review Committee (IRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in clinical decision based on imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response at Study Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Outcome at Test of Cure (TOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD negativity after induction Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with non-serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Severe AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline of subjective vulvovaginal atrophy symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Visual Analogue Scale (VAS) Score for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Traumatic Brain Injury - Quality of Life (TBI-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in measure of patient impression of Telemedicine (TMP-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Caregiver Appraisal Scale (CAS)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Clinical Satisfaction and Competency Rating (CSCR)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in purchasing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: percentage of patients reporting a regular cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Concentration (Cmax) of Insulin Peglispro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of Insulin Peglispro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Drug Concentration (Tmax) of Insulin Peglispro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of ticarcillin-clavulanate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of microaspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy Density (ED) of the Diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of Self-made Meals
Endpoint domain: Life impact
Endpoint subdomain: Dietary habits
Primary endpoint: Maneuvring ergonomical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of recurrent high-grade cervical intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic performance of PI-RADS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Controller accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient wellbeing at 30 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of cases with retained products of conception
Endpoint domain: Adverse events/effects
Primary endpoint: Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in action potential of muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal Cancer Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Colorectal Cancer Death Rates
Endpoint domain: Mortality/survival
Primary endpoint: HD-MTX-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response (no vomiting/retching and no rescue therapy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) for Dose Expansion
Endpoint domain: Mortality/survival
Primary endpoint: Objective Response Rate - Percentage of Participants With Objective Response in Dose Expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of Response (DR) for Dose Expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Failure of Epiphysiodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes